Management and outcomes of chemotherapy-associated pneumoperitoneum in cancer patients: a scoping review protocol

Renee M Maina; Caroline A Rader; Jeevan Kypa; Hilary M Jasmin; Constantine Asahngwa; Clarisse S Muenyi; Denis A Foretia

doi:10.1097/SP9.0000000000000007

Management and outcomes of chemotherapy-associated pneumoperitoneum in cancer patients: a scoping review protocol

Int J Surg Protoc. 2023 Sep 18;27(2):16-19. doi: 10.1097/SP9.0000000000000007. eCollection 2023 Oct.

Authors

Renee M Maina¹, Caroline A Rader², Jeevan Kypa², Hilary M Jasmin³, Constantine Asahngwa⁴, Clarisse S Muenyi¹, Denis A Foretia^{1

5

6

4}

Affiliations

¹ Department of Surgery.
² College of Medicine.
³ Health Science Library.
⁴ Division of Health Policy and Research, Nkafu Policy Institute, Yaoundé, Cameroon.
⁵ Center for Multicultural and Global Health.
⁶ Global Surgery Institute, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

Abstract

Introduction: Pneumoperitoneum - free air within the peritoneal cavity - is often the result of bowel perforation, though other causes include residual postprocedural or postoperative air and barotrauma. In non-cancer patients, operative intervention is often required. Cancer patients, on the other hand, present a unique set of challenges as they usually have elevated risk of pneumoperitoneum from local radiation therapy, frequent endoscopic procedures, and tumor invasion. Factors such as malnutrition, neutropenia, chemotherapy, and steroid use make emergent surgery tenuous in cancer patients. There is a paucity of published literature on the management of pneumoperitoneum in patients actively undergoing chemotherapy. The main objective of this scoping review is to assess the presentation, management, and subsequent outcomes of this unique patient population.

Materials and methods: The authors will utilize the framework for performing scoping reviews as outlined by Arksey and O'Malley. They will perform the search for articles in three electronic databases (i.e. SCOPUS, PubMed, Embase) and relevant gray literature. Only articles available in English and published between 1999 and 2022 will be included. Inclusion criteria will be a known diagnosis of cancer, chemotherapy within 6 months of presentation, and imaging confirmation of pneumoperitoneum. Exclusion criteria will be cancer diagnosis at the time of presentation, perforation secondary to cancer itself, and chemotherapy greater than 6 months prior to presentation. A tailored extraction frame to extract relevant information from published articles that meet our inclusion criteria. The data using both descriptive statistics and thematic analysis of the main study questions.

Ethics and dissemination: Since the authors will not be collecting primary data, formal ethical approval is not required. They study findings will be disseminated through abstracts, conference presentations, and peer-reviewed publications.

Keywords: chemotherapeutic agent; chemotherapy; pneumoperitoneum; scoping review protocol; surgery.